Chris Schott
Stock Analyst at J.P. Morgan
(4.18)
# 1,488
Out of 4,547 analysts
644
Total ratings
57.1%
Success rate
5.3%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintained: Hold | $185 | $203.16 | -8.94% | 19 | Jul 22, 2026 | |
| JNJ Johnson & Johnson | Rated: Hold | $260 → $270 | $250.61 | +7.74% | 20 | Jul 16, 2026 | |
| MRK Merck & Co. | Rated: Buy | $135 → $140 | $126.26 | +10.88% | 34 | Jul 13, 2026 | |
| GILD Gilead Sciences | Maintained: Buy | $160 | $130.28 | +22.81% | 33 | Jul 9, 2026 | |
| ABBV AbbVie | Rated: Buy | $280 | $256.10 | +9.33% | 38 | Jul 9, 2026 | |
| PFE Pfizer | Rated: Hold | $30 → $28 | $24.94 | +12.27% | 89 | Jul 8, 2026 | |
| LLY Eli Lilly and Company | Rated: Buy | $1,400 | $1,175.41 | +19.11% | 71 | Jul 7, 2026 | |
| TEVA Teva Pharmaceutical Industries | Maintained: Buy | n/a | $31.35 | - | 43 | Jun 15, 2026 | |
| REGN Regeneron Pharmaceuticals | Rated: Buy | $950 → $850 | $675.19 | +25.89% | 31 | May 18, 2026 | |
| VTRS Viatris | Rated: Hold | $17 → $18 | $17.59 | +2.33% | 27 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $190 → $130 | $75.35 | +72.53% | 15 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $28 → $30 | $25.48 | +17.74% | 21 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $50 → $58 | $58.42 | -0.72% | 9 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $18.10 | -0.55% | 19 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $18 → $15 | $10.47 | +43.27% | 31 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $12 → $11 | $13.51 | -18.58% | 13 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $65 | $60.93 | +6.68% | 40 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $675 → $775 | $552.46 | +40.28% | 15 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $300 | $366.24 | -18.09% | 11 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $9 → $8 | $1.47 | n/a | 9 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $6.38 | n/a | 41 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $2.04 | n/a | 3 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €84.20 → €85.95 | €136.75 | n/a | 2 | Mar 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $43 → $54 | $25.78 | n/a | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.0001 | n/a | 2 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 | $0.7334 | n/a | 3 | Nov 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $13.93 | n/a | 1 | Oct 17, 2013 |
Biogen
Jul 22, 2026
Maintained: Hold
Price Target: $185
Current: $203.16
Upside: -8.94%
Johnson & Johnson
Jul 16, 2026
Rated: Hold
Price Target: $260 → $270
Current: $250.61
Upside: +7.74%
Merck & Co.
Jul 13, 2026
Rated: Buy
Price Target: $135 → $140
Current: $126.26
Upside: +10.88%
Gilead Sciences
Jul 9, 2026
Maintained: Buy
Price Target: $160
Current: $130.28
Upside: +22.81%
AbbVie
Jul 9, 2026
Rated: Buy
Price Target: $280
Current: $256.10
Upside: +9.33%
Pfizer
Jul 8, 2026
Rated: Hold
Price Target: $30 → $28
Current: $24.94
Upside: +12.27%
Eli Lilly and Company
Jul 7, 2026
Rated: Buy
Price Target: $1,400
Current: $1,175.41
Upside: +19.11%
Teva Pharmaceutical Industries
Jun 15, 2026
Maintained: Buy
Price Target: n/a
Current: $31.35
Upside: -
Regeneron Pharmaceuticals
May 18, 2026
Rated: Buy
Price Target: $950 → $850
Current: $675.19
Upside: +25.89%
Viatris
May 8, 2026
Rated: Hold
Price Target: $17 → $18
Current: $17.59
Upside: +2.33%
May 8, 2026
Rated: Buy
Price Target: $190 → $130
Current: $75.35
Upside: +72.53%
May 7, 2026
Rated: Buy
Price Target: $28 → $30
Current: $25.48
Upside: +17.74%
May 7, 2026
Maintained: Buy
Price Target: $50 → $58
Current: $58.42
Upside: -0.72%
Mar 2, 2026
Maintained: Buy
Price Target: $18
Current: $18.10
Upside: -0.55%
Feb 27, 2026
Maintained: Hold
Price Target: $18 → $15
Current: $10.47
Upside: +43.27%
Feb 13, 2026
Maintained: Sell
Price Target: $12 → $11
Current: $13.51
Upside: -18.58%
Jan 28, 2026
Maintained: Buy
Price Target: $65
Current: $60.93
Upside: +6.68%
Nov 3, 2025
Maintained: Buy
Price Target: $675 → $775
Current: $552.46
Upside: +40.28%
Sep 16, 2025
Maintained: Hold
Price Target: $300
Current: $366.24
Upside: -18.09%
May 25, 2023
Maintained: Hold
Price Target: $9 → $8
Current: $1.47
Upside: n/a
Jul 28, 2022
Downgraded: Hold
Price Target: n/a
Current: $6.38
Upside: n/a
May 19, 2020
Downgraded: Hold
Price Target: n/a
Current: $2.04
Upside: n/a
Mar 9, 2020
Maintained: Buy
Price Target: €84.20 → €85.95
Current: €136.75
Upside: n/a
Feb 20, 2020
Maintained: Hold
Price Target: $43 → $54
Current: $25.78
Upside: n/a
May 13, 2019
Downgraded: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Nov 17, 2017
Maintained: Buy
Price Target: $35
Current: $0.7334
Upside: n/a
Oct 17, 2013
Downgraded: Hold
Price Target: n/a
Current: $13.93
Upside: n/a